Abstract
Endralazine, a new peripheral vasodilator, was given in conjunction with a beta-blocker to 21 patients with hypertension and chronic renal failure. All subjects were either poorly controlled on their previous antihypertensive regime or were experiencing unacceptable adverse effects from drugs. After 4 weeks blood pressure was reduced in all patients and symptomatic side effects were few. Two patients became anti-nuclear factor (ANF) positive in weak titre but without evidence of the lupus syndrome.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bing R. F., Russell G. I., Thurston H., Swales J. D. Hydrallazine in hypertension: is there a safe dose? Br Med J. 1980 Aug 2;281(6236):353–354. doi: 10.1136/bmj.281.6236.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Evans D. A. An improved and simplified method of detecting the acetylator phenotype. J Med Genet. 1969 Dec;6(4):405–407. doi: 10.1136/jmg.6.4.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
- MOYER J. H., HEIDER C., PEVEY K., FORD R. V. The effect of treatment on the vascular deterioration associated with hypertension, with particular emphasis on renal function. Am J Med. 1958 Feb;24(2):177–192. doi: 10.1016/0002-9343(58)90306-1. [DOI] [PubMed] [Google Scholar]
- Perry H. M., Jr Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. Am J Med. 1973 Jan;54(1):58–72. doi: 10.1016/0002-9343(73)90084-3. [DOI] [PubMed] [Google Scholar]
- Perry H. M., Jr, Tan E. M., Carmody S., Sakamoto A. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J Lab Clin Med. 1970 Jul;76(1):114–125. [PubMed] [Google Scholar]